These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30926675)

  • 21. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urothelial cancer: Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum.
    Raman JD
    Nat Rev Urol; 2018 Mar; 15(3):139-140. PubMed ID: 29335525
    [No Abstract]   [Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder.
    McLaren DB
    Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):503-7. PubMed ID: 16238137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on perioperative systemic therapy for urothelial carcinoma.
    Rouvinov K; Plimack ER; Zibelman M; Ghatalia P; Geynisman DM
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):176-183. PubMed ID: 30969956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J. Bivalacqua and P. M. Pierorazio J Urol 2018;200:68-73.
    Xue W; Yang L; Wei Q
    J Urol; 2018 Dec; 200(6):1378-1379. PubMed ID: 30172893
    [No Abstract]   [Full Text] [Related]  

  • 26. [Systemic treatment of bladder cancer].
    Haas M; Burger M; Schnabel MJ
    Urologe A; 2021 Sep; 60(9):1167-1174. PubMed ID: 34043031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022;82:212-22.
    Zhao Z; Guo H; Yang R
    Eur Urol; 2022 Dec; 82(6):e176. PubMed ID: 36195479
    [No Abstract]   [Full Text] [Related]  

  • 28. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
    Gravis G; Billon E; Baldini C; Massard C; Hilgers W; Delva R; Walz J; Pignot G; Rybikowski S; Dermeche S; Thomassin J; Brunelle S; Lavaud P; Loriot Y;
    Eur J Cancer; 2018 Nov; 104():236-238. PubMed ID: 30316610
    [No Abstract]   [Full Text] [Related]  

  • 29. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iatrogenic pathology of the urinary bladder.
    Lopez-Beltran A; Montironi R; Raspollini MR; Cheng L; Netto GJ
    Semin Diagn Pathol; 2018 Jul; 35(4):218-227. PubMed ID: 29576423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.
    O'Donnell PH; Alanee S; Stratton KL; Garcia-Grossman IR; Cao H; Ostrovnaya I; Plimack ER; Manschreck C; Ganshert C; Smith ND; Steinberg GD; Vijai J; Offit K; Stadler WM; Bajorin DF
    Clin Genitourin Cancer; 2016 Dec; 14(6):511-517. PubMed ID: 27150640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
    Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic models for patients with metastatic urothelial carcinoma: why use them?
    Maffezzoli M; Campobasso D; Rebuzzi SE; Banna GL; Fornarini G; Signori A; Rescigno P; Buti S
    Minerva Urol Nephrol; 2023 Aug; 75(4):419-421. PubMed ID: 37166132
    [No Abstract]   [Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer.
    Sonpavde G; Amiel GE; Mims MP; Hayes TG; Lerner SP
    Expert Opin Pharmacother; 2008 Aug; 9(11):1885-93. PubMed ID: 18627327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
    Szarvas T; Oláh C; Riesz P; Géczi L; Nyirády P
    Orv Hetil; 2019 Oct; 160(42):1647-1654. PubMed ID: 31608691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Geynisman DM; Abbosh PH; Plimack ER; Zibelman M
    Eur Urol; 2018 May; 73(5):760-762. PubMed ID: 29331216
    [No Abstract]   [Full Text] [Related]  

  • 38. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG).
    Zagouri F; Peroukidis S; Tzannis K; Kouloulias V; Bamias A;
    Crit Rev Oncol Hematol; 2015 Jan; 93(1):36-49. PubMed ID: 25205597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
    Marchioni M; Nazzani S; Preisser F; Bandini M; Karakiewicz PI
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):377-387. PubMed ID: 29429376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.